- Long-term efficacy and safety results of an integrated data set for Vitrakvi® (larotrectinib), as well as sub-analyses, to be presented in poster sessions
- Tolerability and treatment response data from the Phase III ARAMIS trial investigating NUBEQA® (darolutamide) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)
- Continued research to explore potential of marketed products, evaluating the investigational use of Stivarga® (regorafenib) and Xofigo® (radium Ra 223 dichloride) in combination with immunotherapies
Posters: 1955P, 1916P, 1289P, 542P, 604TiP, 132P, 633P, 694TiP, 631P, LBA68, 990P, 465P, 1010P, 1009P, 829P, 1918P, 1420TiP, 637P, 639P
San Francisco, California (UroToday.com) Data from Bayer’s evolving oncology portfolio will be presented at the ESMO Virtual Congress 2020, taking place on September 19-21, 2020. Presentations will highlight therapies from Bayer that evaluate patient outcomes as well as safety and efficacy in different tumor types. Other presentations include investigational use of therapies in combination with immunotherapies. Information on the registration as well as the virtual scientific program can be found here.